Overview

Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing

Status:
Withdrawn
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The investigators would like to investigate the efficacy of more frequent treatment with Lucentis for subjects with persistent diabetic macular edema despite standard dosing regimen.
Phase:
Phase 2
Details
Lead Sponsor:
Maturi, Raj K., M.D., P.C.
Treatments:
Ranibizumab